Experimental models reinforce these findings: ERRα knockout animals show heightened inflammatory responses, while ERRα agonists reduce cytokine expression and inflammation in models of obesity, atherosclerosis, and neuroinflammation [202]. Here, ESRRA is linked to atherosclerosis.